arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Janux Therapeutics, Inc.

JANX
$16.50 ▼ -0.97 (-5.55%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Neutral
auto_awesome

Analytical Summary

Janux Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.0B
Dividend Yield —
Revenue Growth None
Op. Margin -308.7%
ROIC -2.7% ↗
FCF / Share $0.20 ↗
Trailing P/E —
Price / Book 1.1x
FCF Yield 1.2%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.27M
↑ +175.0% —
Net Income Profit after all expenses
$-21.97M
↑ +35.1% —
Operating Margin Operating profit as % of sales
-308.7%
↑ +12.4% —
FCF / Share Free cash flow per share
$0.20
↑ +197.0% —

Health Breakdown

Returns ↓
33
Cash Quality ↑
50

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters